MINIject® is seeking to transform the glaucoma treatment landscape with its distinctive, tissue-integrating STAR® material. MINIject® is currently the only commercially available minimally invasive glaucoma surgery (MIGS) implant that enhances natural flow in the supraciliary space, and has been shown to deliver safe, meaningful and sustained control of intraocular pressure (IOP).
MINIject® is a novel MIGS device for patients with open-angle glaucoma, made of an innovative medical-grade silicone material called STAR®. MINIject® has been shown to safely and meaningfully control eye pressure and glaucoma through:
STAR® material is composed of a multi-channel network of hollow spheres making it soft and flexible while encouraging bio-integration. iSTAR Medical believes this distinctive combination of material and outflow enables MINIject® to deliver sustained efficacy.
MINIject® is only available for sale in the European Union, the UK and Switzerland.
Denis P, Hirneiß C, Durr GM, et al. Br J Ophthalmol 2020;0:1–6
SEE MORE ABOUT MINIJECT
SEE MORE ABOUT GLAUCOMA
Source: Market Scope, “2021 Glaucoma Surgical Device Market Report”, July 2021; Jonas JB, Aung T, Bourne RR et al, “Glaucoma”, Lancet 2017; 390: 2083–93
iSTAR Medical is a medtech company committed to delivering breakthrough eye care solutions through minimally-invasive implants designed for bio-integration. Our mission is to become the world leader in minimally invasive implants for glaucoma surgery.
iSTAR Medical received European approval for the MINIject MIGS device in late 2021 and began enrolment into an FDA-approved clinical trial (STAR-V) in the United States in 2021. Since 2023, it is also approved for implantation in Australia.
